Use of D-arginine and/or L-arginine to protect the amino groups of biological substances from damage, inactivation, or modification by toxic carbonyls and/or dicarbonyls

• US 6,727,285 B1
• Filed: 05/14/1998
• Issued: 04/27/2004
• Est. Priority Date: 11/07/1995
• Status: Expired due to Fees

• Current Assignee: George M. Haik Jr
• Original Assignee: George M. Haik Jr
• Inventors: Haik, George M. Jr.
• Primary Examiner(s): BORIN, MICHAEL L
• Application Number:
  US09/079,329
• Time in Patent Office: 2,175 Days
• Field of Search: 514/631
• US Class Current: 514/565
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00

Abstract

A method of blocking dicarbonyls and carbonyls in vitro and in vivo includes using an effective quanity of an L- or D-arginine, substituted arginine, modified arginine or arginine-containing blocking agent. The method can, for example, include blocking toxic dicarbonyls and carbonyls in a patient suffering from a condition associated with toxic carbonyls and/or dicarbonyls, by administering to the patient a therapeutically effective dose of an L- or D-arginine, substituted arginine, modified arginine or arginine-containing blocking agent.

Claims

1. A method of blocking toxic carbonyl containing compounds and/or dicarbonyl containing compounds in a subject suffering from a condition associated with carbonyl containing compounds and/or dicarbonyl containing compounds by treating blood and/or blood products in a dialysis system for return to the subject comprising administering in the dialysis system a therapeutically effective dose of D-arginine to the subject'"'"'s blood and/or blood products.

2. The method of claim 1, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.001 mg/100 ml to 60 mg/100 ml of arginine hydrochloride to blood or blood products.

3. The method of claim 1, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.005 mg/100 ml to 50 mg/100 ml of arginine hydrochloride to blood or blood products.

4. The method of claim 1, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.5 mg/100 ml to 40 mg/100 ml of arginine hydrochloride to blood or blood products.

5. A method of treating a subject suffering from diabetes mellitus by treating blood and/or blood products in a dialysis system for return to the subject comprising administering in the dialysis system a therapeutically effective dose of D-arginine to the subject'"'"'s blood and/or blood products.

6. The method of claim 5, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.001 mg/100 ml to 60 mg/100 ml of arginine hydrochloride to blood or blood products.

7. The method of claim 5, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.005 mg/100 ml to 50 mg/100 ml of arginine hydrochloride to blood or blood products.

8. The method of claim 5, wherein the D-arginine is administered to blood or blood products, as filterable wash or unremoved treatment, and at molar concentrations of arginine equal to 0.5 mg/100 ml to 40 mg/100 ml of arginine hydrochloride to blood or blood products.